Dementia and Psychosis in Parkinson's, Alzheimer's, and Lewy Body Disease:Understanding the Differences in 2026
By Michael Dauer, MS, MBA
Research Director, Inland Northwest Research
Dementia and psychosis are two of the most impactful — and most commonly misunderstood — features of neurodegenerative disease. For families navigating a diagnosis of Parkinson's disease (PD), Alzheimer's disease (AD), or dementia with Lewy bodies (DLB), these symptoms often raise some of the hardest questions: What is driving them? Will they progress? Do the treatments that help one condition also help another?
The short answer is that while these three diseases can share overlapping symptoms, the timing, pattern, and underlying biology differ in important ways. In 2026, as research increasingly moves toward disease-modifying therapies — treatments designed to slow the disease process rather than only manage symptoms — accurate diagnosis matters more than ever. A therapy developed for one condition may not be appropriate, or safe, for another. This article offers a plain-language overview of how dementia and psychosis differ across PD, AD, and DLB, and why those distinctions shape both clinical care and the next generation of research.
Please note: This article is intended as general educational information. It does not constitute medical advice. Individuals with concerns about memory, cognition, hallucinations, or changes in perception should consult their treating neurologist or primary care provider.
Dementia and Psychosis: Two Different Things
Because these terms are sometimes used interchangeably in casual conversation, it helps to define them precisely.
Dementia refers to a decline in cognitive function significant enough to interfere with daily life. It can include memory impairment, reduced attention and concentration, difficulty with planning and decision-making, and changes in language or visual-spatial ability.
Psychosis refers to a loss of contact with reality. In neurodegenerative disease, the most common manifestations are visual hallucinations (seeing people, animals, or scenes that are not there) and delusions (fixed false beliefs, often involving paranoia, misidentification, or false convictions about family members).
Both dementia and psychosis can occur in PD, AD, and DLB. But they do not appear on the same timeline, in the same form, or for the same reasons in each disease. Understanding those differences is essential to accurate diagnosis and appropriate treatment.
How the Three Diseases Present
Alzheimer's disease is primarily a disorder of memory. The earliest symptoms typically involve short-term memory loss and difficulty learning new information. As the disease progresses, language impairment, disorientation, and impaired judgment become more prominent. Psychosis — most often in the form of delusions — tends to emerge in later stages, though visual hallucinations can also occur.
Parkinson's disease is defined by motor symptoms early in its course. Tremor at rest, rigidity, and bradykinesia (slowness of movement) are the hallmarks. Non-motor features, including slowed thinking, executive dysfunction, and attention deficits, often emerge later. Psychosis in Parkinson's most commonly takes the form of visual hallucinations, and it is influenced by both the disease itself and by dopaminergic therapy. When dementia develops after established Parkinson's motor symptoms, it is specifically termed Parkinson's disease dementia (PDD).
Dementia with Lewy bodies presents differently from either. Cognitive and neuropsychiatric symptoms appear early — attention deficits, visual-spatial dysfunction, and fluctuating cognition are often among the first features. Visual hallucinations are common from the outset. Motor symptoms resembling Parkinson's are present but frequently less prominent initially. REM sleep behavior disorder (acting out dreams during sleep) and a marked sensitivity to certain medications are also characteristic.
Timing: Parkinson's Disease Dementia vs. Lewy Body Dementia
A single clinical rule separates these two related conditions: In Parkinson's disease dementia, cognitive decline occurs years after motor symptoms have been established. In dementia with Lewy bodies, cognitive symptoms occur either before, or within one year of, the onset of motor symptoms.
This distinction reflects differences in where Lewy body pathology first appears and how it spreads through the brain, even though both conditions share the same underlying pathology: the abnormal accumulation of alpha-synuclein protein. The difference in timing has real implications for how symptoms are recognized, how medications are selected, and what families should expect.
Comparing Dementia Profiles Across Conditions
The cognitive profile is not the same in each disease, and the differences can guide both diagnosis and care planning.
In Alzheimer's disease, the core deficit is in memory encoding and storage. New information is difficult to learn, and recent events are frequently forgotten, while older memories may remain relatively preserved until later stages.
In Parkinson's disease dementia, the pattern is different. Memory can be impaired, but the more prominent features tend to be slowed processing speed, difficulty with executive function (planning, multitasking, switching between tasks), and difficulty retrieving information that is, in fact, stored.
In dementia with Lewy bodies, the most characteristic features are impaired attention, visual-spatial dysfunction, and fluctuations in cognition — periods of relative clarity alternating with periods of confusion that can vary from hour to hour. These fluctuations are particularly distinctive and can initially be mistaken for other causes.
Comparing Psychosis Profiles Across Conditions
Psychosis also looks different across the three diseases:
In Alzheimer's disease, psychotic features typically emerge in later stages and often involve delusions — common themes include the belief that items have been stolen or that a familiar person has been replaced by an imposter (Capgras-type misidentification).
In Parkinson's disease, psychosis often begins with visual hallucinations and can start subtly, with a sense of presence (feeling someone is nearby when no one is there) or passage hallucinations (fleeting glimpses of movement at the edge of vision). Formed visual hallucinations — seeing specific people or animals — can follow. Dopaminergic medications can contribute to these symptoms, which is one reason medication adjustment is often part of management.
In dementia with Lewy bodies, visual hallucinations appear early and are frequently well-formed and detailed: specific people, animals, or complex scenes. They can occur even when overall cognitive impairment is relatively mild.
An important point: in Lewy body disorders (both PD and DLB), hallucinations reflect disruptions in perception and attention networks, not simply memory loss. This is why they can appear before significant cognitive decline and why they do not necessarily indicate that dementia is imminent.
What's Happening in the Brain
The biology explains much of the difference.
Alzheimer's disease is driven by accumulation of amyloid-beta plaques and tau neurofibrillary tangles. These changes primarily affect memory-related regions such as the hippocampus and temporal lobes, which is why memory impairment dominates the clinical picture.
Parkinson's disease and dementia with Lewy bodies are both characterized by the accumulation of alpha-synuclein protein, which forms the Lewy bodies that give these disorders their name. The distribution is different, but the underlying pathology is shared.
Lewy body disorders also involve significant disruption in neurotransmitter systems beyond the ones typically discussed: Dopamine loss contributes to motor symptoms and can influence psychosis, especially in the context of dopaminergic treatment. Acetylcholine deficits are strongly associated with cognitive impairment and with visual hallucinations. This is one of the reasons cholinesterase inhibitors have a clinical role in Lewy body disorders that is distinct from their role in Alzheimer's disease.
The combination of widespread network disruption plus neurotransmitter imbalance helps explain why hallucinations, attention deficits, and cognitive fluctuations are so prominent in PD and DLB, and why these symptoms can appear even when memory is still relatively intact.
Why This Matters for Treatment
Accurate diagnosis directly affects care decisions, and in Lewy body disorders specifically, it can affect safety.
Patients with Lewy body disease are particularly sensitive to certain antipsychotic medications, which can worsen motor symptoms or, in some cases, lead to severe adverse reactions. This is one of the clearest examples of why distinguishing DLB from AD matters practically: a standard approach to managing psychosis in one condition can be harmful in another.
Broader treatment approaches may include adjusting dopaminergic therapy in Parkinson's disease; the use of cholinesterase inhibitors (such as rivastigmine), which have evidence supporting their use for both cognitive symptoms and hallucinations in Lewy body disorders; and non-pharmacologic strategies such as structured routines, sleep optimization, and environmental modifications.
When to Seek Evaluation
Neurological evaluation is warranted when there are new or worsening cognitive changes; visual hallucinations or changes in perception; fluctuations in alertness or attention; behavioral or personality changes; or sleep disturbances involving acting out of dreams. Early recognition allows for more targeted management and clearer communication among the individual, their family, and their care team.
Why This Matters for Clinical Research
For most of the history of these diseases, treatment has focused on symptom management. In 2026, that is beginning to change. Research is actively investigating therapies that aim to slow, modify, or interrupt the underlying disease process itself — targeting amyloid and tau in Alzheimer's disease, alpha-synuclein in PD and DLB, and the pathways that drive cognitive decline and neuropsychiatric symptoms across all three.
This shift makes accurate diagnosis more important than it has ever been. A therapy developed for one pathology may not benefit another, and the specific symptoms a person experiences — whether dementia predominates, whether psychosis is present, when in the disease course those symptoms appeared — are increasingly used to define which clinical trials a given individual may be a candidate for.
At Inland Northwest Research, we are preparing to participate in research studies focused on the cognitive and neuropsychiatric features of these conditions. We cannot yet announce specific enrollment opportunities, because any study we publicize must first receive full IRB approval. We can, however, connect with individuals and families who want to be notified as these opportunities open. Reaching out does not enroll you in a study, but allows us to contact you if appropriate research opportunities become available.
If you or a loved one has been diagnosed with Parkinson's disease, Alzheimer's disease, or dementia with Lewy bodies, and you are interested in learning about future research opportunities, please reach out to our team at (509) 960-2818 or contact@inwresearch.com. Connecting early allows us to follow up when a study relevant to your diagnosis opens.
A Final Perspective
Dementia and psychosis are not uniform across neurodegenerative disease. The timing, the symptom profile, and the underlying biology differ meaningfully among Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies. Recognizing those distinctions leads to more accurate diagnosis, safer treatment decisions, and a clearer path forward for patients and families navigating some of the most difficult questions in neurology.
About Clinical Research at Inland Northwest Research
Inland Northwest Research actively participates in clinical research across the full spectrum of movement disorders and neurodegenerative conditions, including Parkinson's disease, Multiple System Atrophy, Huntington's disease, Dystonia, Essential Tremor, and related conditions. Our research portfolio evolves as the science evolves, and new studies are continuously entering development.
We post new research opportunities on our website only after they have received IRB approval and are formally open for enrollment. This ensures that any study we publicize has undergone independent ethical review and that participants can be properly informed and screened.
Research vs. Treatment: An Important Distinction
Inland Northwest Research is a clinical trial site, not a primary care clinic. Our sister organization, Selkirk Neurology, provides established medical treatments and symptom management under the direction of Dr. Jason Aldred. INWR conducts regulated clinical studies designed to evaluate investigational drugs and devices. If you are seeking treatment for a diagnosed condition, your neurologist or primary care provider is the appropriate first point of contact.
How to Stay Informed About Future Studies
If you would like to be notified when dementia or psychosis studies open for enrollment at INWR, reach out at (509) 960-2818 or contact@inwresearch.com. Connecting early allows us to contact you when relevant opportunities become available.